688315 Novogene Co., Ltd.
- 14.39
- +0.17+1.20%
Novogene Co., Ltd. News
Novo Zhiyuan (688315.SH): The 2023 profit distribution plan proposes to adjust the cash dividend per share to 0.0475 yuan
Glonghui, May 13, 丨 Novo Zhiyuan (688315.SH) announced that from the date of disclosure of the 2023 profit distribution plan until the disclosure date of this announcement, the company carried out repurchases through centralized bidding transactions through the Shanghai Stock Exchange trading system. Therefore, the number of shares actually participating in the distribution changed. The company adjusted the distribution ratio per share of the company's 2023 profit distribution plan accordingly in accordance with the principle that the total distribution amount was unchanged and the distribution ratio per share was adjusted accordingly. According to changes in the number of shares actually participating in the distribution, the company distributes each share in accordance with the principle that the total amount distributed remains unchanged and the distribution ratio per share is adjusted accordingly
Novo Genesis (688315.SH): Focus on pioneering the application of cutting-edge molecular biology technology and high-performance computing in life science research and human health
Gelonghui, May 8 | Novo Zhiyuan (688315.SH) said on an interactive platform that the company focuses on pioneering the application of cutting-edge molecular biology technology and high-performance computing in life science research and human health, and is committed to becoming the world's leading provider of gene technology products and services. Currently, the business covers basic life science research services, medical research and technical services, and database sequencing platform services, providing services such as gene sequencing, mass spectrometry analysis, and bioinformation technology support for global research universities, research institutes, hospitals, pharmaceutical R&D enterprises, agricultural enterprises, etc.
Novo Zhiyuan (688315.SH): 1.89% of shares have been repurchased
Gelonghui, May 7, 丨 Novo Zhiyuan (688315.SH) announced that as of April 30, 2024, the company had repurchased a total of 7,853,344 shares through the Shanghai Stock Exchange trading system, accounting for 1.89% of the company's total share capital. The highest price of the repurchase transaction was 15.86 yuan/share, the lowest price was 12.56 yuan/share, and the total amount of capital paid was RMB 107,766,414.08 (excluding transaction fees such as stamp duty and transaction fees).
News Flash: 3 Analysts Think Novogene Co., Ltd. (SHSE:688315) Earnings Are Under Threat
Today is shaping up negative for Novogene Co., Ltd. (SHSE:688315) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue and earnings per share
Zhitong A Share Sale Restriction and Release List | April 24
According to the Zhitong Finance App, the ban on restricted shares of 7 listed companies was lifted on April 24, with a total market value of about 4.796 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Siquan Xincai 301489A shares, the issuing corporation placed 745,200, Emma Technology 603,529, share incentives, 4.123,800 Merisin 301,307 shares were restricted from sale and circulation before issuance, 573511 Wanhausen Smart 6885293.84 million, Novo Zhiyuan 68831516 million Aerospace Technology 6882391372 million Jingsheng shares
Novo Zhiyuan (688315.SH): The ban on 16 million restricted shares was lifted on April 24
Gelonghui, April 16 | Novo Zhiyuan (688315.SH) announced that the total number of shares in circulation during the current listing of the company is 16 million shares. The stock listing and circulation date is April 24, 2024.
Novo Zhiyuan (688315.SH): 1.40% of the company's shares have been repurchased
Gelonghui, April 15, 丨 Novo Zhiyuan (688315.SH) announced that as of April 15, 2024, the company had repurchased a total of 5,813,109 shares through the Shanghai Stock Exchange trading system, accounting for 1.40% of the company's total share capital, an increase of 0.62% compared with the previous disclosure. The highest price of the repurchase transaction was 15.86 yuan/share, the lowest price was 12.77 yuan/share, and the total amount of capital paid was RMB 8,14.305 million (excluding transaction fees such as stamp duty and transaction fees).
Novo Zhiyuan (688315.SH) announced first-quarter results, net profit of 273.154 million yuan, an increase of 21.4% over the previous year
Novo Zhiyuan (688315.SH) released its report for the first quarter of 2024. The company's revenue was 468 million yuan...
Novo Zhiyuan (688315.SH): The ban on 290 million restricted shares was lifted on April 15
Gelonghui, April 3 | Novo Zhiyuan (688315.SH) announced that the total number of shares in circulation during the current stock listing of the company is 290 million shares. The stock listing and circulation date is April 15, 2024.
Novo Zhiyuan (688315.SH): A total of 0.77% of the company's shares have been bought back at a cost of 477.47,500 yuan
Gelonghui, April 2, 丨 Novo Zhiyuan (688315.SH) announced that as of March 31, 2024, the company had repurchased a total of 3.2251 million shares through the Shanghai Stock Exchange trading system, accounting for 0.77% of the company's total share capital. The highest price of the repurchase transaction was 15.86 yuan/share, the lowest price was 13.93 yuan/share, and the total amount of capital paid was RMB 477.475 million (excluding transaction fees such as stamp duty and transaction fees).
What Does Novogene Co., Ltd.'s (SHSE:688315) Share Price Indicate?
While Novogene Co., Ltd. (SHSE:688315) might not have the largest market cap around , it saw a decent share price growth of 15% on the SHSE over the last few months. The recent rally in share pr
Novo Zhiyuan (688315.SH): A total of 50,000 shares have been repurchased
Gelonghui, March 1, 丨 Novo Zhiyuan (688315.SH) announced that as of February 29, 2024, the company had repurchased 50,000 shares of the company's shares through centralized bidding transactions, accounting for 0.012% of the company's total share capital. The highest repurchase transaction price was 15.86 yuan/share, the lowest price was 15.20 yuan/share, and the total amount of capital paid was RMB 771,035.08 (excluding transaction fees such as stamp duty and transaction commissions).
Novo Zhiyuan (688315.SH) performance report: 2023 net profit of 177 million yuan, up 0.11% year on year
Glonghui, Feb. 27丨Novo Zhiyuan (688315.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 2.02 billion yuan, an increase of 3.98%; realized net profit attributable to owners of the parent company of 177 million yuan, an increase of 0.11%; and realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 138 million yuan, a year-on-year decrease of 10.18%.
Some Novogene Co., Ltd. (SHSE:688315) Shareholders Look For Exit As Shares Take 29% Pounding
To the annoyance of some shareholders, Novogene Co., Ltd. (SHSE:688315) shares are down a considerable 29% in the last month, which continues a horrid run for the company. For any long-term shareho
Novo Zhiyuan (688315.SH): Chairman and General Manager Li Ruiqiang proposed to buy back 80 million yuan to 160 million yuan of shares
Glonghui, January 31, 丨 Novo Zhiyuan (688315.SH) announced that on January 31, 2024, the company received a “Letter on Proposing Beijing Novo Zhiyuan Technology Co., Ltd. to repurchase the company's shares” from Mr. Li Ruiqiang, the company's actual controller, chairman and general manager. Mr. Li Ruiqiang proposed that the company use its own funds to repurchase some of the company's issued RMB common shares (A shares) through the Shanghai Stock Exchange trading system. The total capital for the repurchase of the shares is not less than RMB 80 million (inclusive), and not more than RMB 160 million (inclusive) (inclusive) ); Price for repurchasing shares:
Novogene Co., Ltd.'s (SHSE:688315) Intrinsic Value Is Potentially 21% Below Its Share Price
Key Insights The projected fair value for Novogene is CN¥14.89 based on 2 Stage Free Cash Flow to Equity Novogene's CN¥18.91 share price signals that it might be 27% overvalued Our fair value esti
Risks To Shareholder Returns Are Elevated At These Prices For Novogene Co., Ltd. (SHSE:688315)
With a price-to-earnings (or "P/E") ratio of 48.3x Novogene Co., Ltd. (SHSE:688315) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios under
Novogene Co., Ltd. (SHSE:688315) CEO Ruiqiang Li, the Company's Largest Shareholder Sees 5.7% Reduction in Holdings Value
Key Insights Insiders appear to have a vested interest in Novogene's growth, as seen by their sizeable ownership Ruiqiang Li owns 54% of the company Institutional ownership in Novogene is 17% Ev
[Instant Analysis of BT Financial Report] Novo Zhiyuan 2023 Third Quarter Report: Balance ratio declined, net profit increased, net cash flow declined due to VAT
Announcement time of this financial report: 2023-10-24 16:52:50 Novo Zhiyuan (stock code: 688315) is a technology service enterprise focusing on gene sequencing technology and bioinformation analysis technology. The company has established a global technical service network, with laboratories and subsidiaries, and its business covers about 90 countries and regions on six continents. The company has achieved remarkable results in the field of scientific research. The number of SCI articles published or mentioned exceeds 20,000, and has 62 patents related to gene sequencing technology and 320 software copyrights. From the perspective of assets and liabilities, Novartis
Novo Zhiyuan (688315.SH): The future trend is that the industry has more and more platform options
Gelonghui, October 26|Novo Zhiyuan (688315.SH) said in response to a survey of specific targets that currently many upstream domestic and foreign companies have launched commercialization platforms, so the future trend is that there are more and more opportunities for the industry to choose platforms. Overall, however, the market base of these new platforms is still in its early stages, and the penetration rate and share of the entire market may still be relatively limited. Judging from the company's choices, the company's choice of upstream platforms is open. As a midstream service provider, the company is more likely to address customer needs. In the future, with the two-way choice of market and supply, upstream instruments will also be affected
Analysis
Price Target
No Data
